Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.50 |
| ▸ | PI4KA | P42356 | 11/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 11/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 11/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28296105 | 0.87 | ADORA2A (0.47) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5089696 | 0.82 | ENPP1 (0.46) | — | |
| SCHEMBL1272854 | 0.78 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL887808 | 0.77 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL385843 | 0.77 | ADORA2A (0.55) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23397838 | 0.77 | ADORA2A (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL283730 | 0.74 | FGFR1 (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL14125909 | 0.74 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5663802 | 0.74 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23834271 | 0.73 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8852407-B2 | Electron beam sculpting of tunneling junction for nanopore DNA sequencing | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2014-10-07 | — | — | US | claimed |
| EP-3515923-A1 | PRODRUGS OF FLUORINATED ACYCLIC NUCLEOSIDE PHOSPHONATES | Katholieke Universiteit Leuven (BE) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018055071-A1 | PRODRUGS OF FLUORINATED ACYCLIC NUCLEOSIDE PHOSPHONATES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2018-03-29 | — | — | WO | disclosed |
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| EP-2980095-A1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.Leuven Research & Development (BE) | 2016-02-03 | — | — | EP | disclosed |
| US-9249177-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-14 | — | — | US | disclosed |
| US-9222930-B2 | Fabrication of tunneling junction for nanopore DNA sequencing | GLOBALFOUNDRIES INC. (KY) | 2015-12-29 | — | — | US | disclosed |
| US-9046511-B2 | Fabrication of tunneling junction for nanopore DNA sequencing | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2015-06-02 | — | — | US | disclosed |
| EP-1720890-B1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | LEUVEN K U RES & DEV (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-0630381-B1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1997-04-09 | — | — | EP | disclosed |
| EP-0269947-B2 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1996-10-16 | — | — | EP | disclosed |
| EP-0452935-B1 | Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1995-06-21 | — | — | EP | disclosed |
| EP-0630381-A4 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | — | 1995-01-04 | — | — | EP | disclosed |
| EP-0630381-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1994-12-28 | — | — | EP | disclosed |
| US-5302585-A | Viricides, HIV virus | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-04-12 | — | — | US | disclosed |
| WO-1993007157-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-04-15 | — | — | WO | disclosed |
| EP-0481214-A1 | Prodrugs of phosphonates | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1992-04-22 | — | — | EP | disclosed |
| EP-0452935-A1 | Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1991-10-23 | — | — | EP | disclosed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | ADORA2A 58/4885ADORA1 117/4885PI4KA 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.